
PATIENT MATERIALS

Patient Reminder Card

Doctor's name:

Telephone:

Oral retinoids products containing acitretin, alitretinoin and isotretinoin must not be taken during pregnancy.

Oral retinoids products containing acitretin, alitretinoin and isotretinoin **can seriously harm an unborn baby** if a pregnant woman takes it.

If you become pregnant or think you might be pregnant, stop taking oral retinoids products containing acitretin, alitretinoin and isotretinoin immediately and contact your doctor.

Read the package leaflet carefully before you start treatment.

If you have any questions or concerns about taking oral retinoids products containing acitretin, alitretinoin and isotretinoin, talk to your doctor or pharmacist.

What you have to do if you could become pregnant:

- **You must use at least 1 highly effective method of contraception (such as an intra-uterine device or an implant) or correctly use 2 effective methods of birth control that work in different ways (such as an oral contraceptive together with a condom) before, during and for 1 month [3 years for acitretin] after stopping treatment.**
- **You must not become pregnant while taking oral retinoids products containing acitretin, alitretinoin and isotretinoin, or for 1 month [3 years for acitretin] after stopping treatment.**
- **You must attend regular follow-up visits and have regular pregnancy testing:**
 - ✓ Before you start treatment, you will have to have a pregnancy test, which must be negative.
 - ✓ To make sure you are not pregnant during treatment, you should have regular pregnancy tests, ideally every month. You should also have a final pregnancy test 1 month [for acitretin should be every 1-3 months for a period of 3 years] after stopping treatment.

Reminder for men and women

This medication has been prescribed to you only, **do not share it with anybody and return any unused capsules back to the pharmacy.**

APPOINTMENT TABLE (please use this table to record the dates of your appointments with your doctor)

Doctor's name:

Telephone:

Date of appointment	Contraception used	Pregnancy test result	Doctor's signature
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	
		<input type="checkbox"/> Positive <input type="checkbox"/> Negative Date:	

Reporting of suspected adverse reactions/ exposure during pregnancy

Any suspected adverse reactions or pregnancies occurring during treatment and within 1 month [3 years for acitretin] following discontinuation of treatment should be reported to the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warszawa, tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309, e-mail: ndl@urpl.gov or to Marketing Authorization Holder in Poland.

The **electronic version** of educational materials can be found on the Marketing Authorization Holder's or/and dedicated website.